MC
BIIB icon

Middleton & Co’s Biogen BIIB Stock Holding History

Middleton & Co’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,258
Closed -$1.77M – 155
2016
Q4 		$1.77M Sell
6,258
-2,828
-31% -$838K 0.4% 71
2016
Q3 		$2.84M Sell
9,086
-7,750
-46% -$2.3M 0.64% 51
2016
Q2 		$4.07M Sell
16,836
-3,636
-18% -$958K 0.94% 35
2016
Q1 		$5.33M Buy
20,472
+1,152
+6% +$304K 1.24% 31
2015
Q4 		$5.92M Sell
19,320
-3,046
-14% -$875K 1.32% 26
2015
Q3 		$6.53M Buy
22,366
+1,422
+7% +$470K 1.55% 25
2015
Q2 		$8.46M Buy
20,944
+1,906
+10% +$765K 1.83% 16
2015
Q1 		$8.04M Buy
19,038
+873
+5% +$344K 1.76% 18
2014
Q4 		$6.17M Buy
+18,165
New +$5.88M 1.38% 25

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Middleton & Co's BIIB Position: Q1 2017 in Review

Middleton & Co sold out of Biogen (BIIB) in Q1 2017, closing a stake of 6,258 shares — an estimated $1.77M sold.

Middleton & Co first reported a position in BIIB in Q4 2014 and held it in 9 quarters. The position peaked at $8.46M in Q2 2015. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

  • Middleton & Co reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
  • Middleton & Co sold 6,258 Biogen shares in Q1 2017, an estimated $1.77M.
  • Middleton & Co first reported a position in Biogen in Q4 2014 and held it in 9 quarters.
  • Middleton & Co's Biogen position peaked at $8.46M in Q2 2015.
  • 1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on Middleton & Co's 13F filing for Q1 2017, filed 19 Apr 2017.